Πέμπτη 11 Ιανουαρίου 2018

A SUV max -based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making

Abstract

Background

The value of maximum standard uptake value (SUVmax) was overlooked in current studies comparing stereotactic body radiotherapy (SBRT) versus surgery for stage I non-small cell lung cancer (NSCLC). Herein, we aimed to compare the 3-year outcomes based on patients for whom SUVmax were available, and to explore the role of SUVmax in clinical decision-making.

Methods

From January 2010 to June 2016, data of eligible patients were collected. Patient variables and clinical outcomes were compared in both unmatched and matched groups using propensity score matching (PSM). Multivariate analysis was performed for predictors of poor outcome. The relationship between treatment approach and survival outcome was also evaluated in subgroup patients stratified by SUVmax level.

Results

A total of 425 patients treated with either surgery (325) or SBRT (100) were included. Patients receiving SBRT were significantly older, had a higher level of SUVmax and were more likely to have tumor of centrally located. Multivariate analysis showed that SUVmax and tumor size were significant predictors for 3-year OS, LRC, and PFS, while better PFS was also related to peripheral tumor and surgery. The result of PSM analysis also showed that compared to SBRT, surgery could only achieve better PFS. Subgroup analysis indicated that surgery had added advantage of 3-year LRC and PFS for patients in high SUVmax group (SUVmax > 8), but not in low SUVmax group.

Conclusions

The study found a superior PFS after surgery while OS and LRC did not differ between SBRT and surgery. Surgery should be recommended for tumor of high SUVmax.



from Cancer via ola Kala on Inoreader http://ift.tt/2qXiZ5b
via IFTTT

A SUV max -based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making

Abstract

Background

The value of maximum standard uptake value (SUVmax) was overlooked in current studies comparing stereotactic body radiotherapy (SBRT) versus surgery for stage I non-small cell lung cancer (NSCLC). Herein, we aimed to compare the 3-year outcomes based on patients for whom SUVmax were available, and to explore the role of SUVmax in clinical decision-making.

Methods

From January 2010 to June 2016, data of eligible patients were collected. Patient variables and clinical outcomes were compared in both unmatched and matched groups using propensity score matching (PSM). Multivariate analysis was performed for predictors of poor outcome. The relationship between treatment approach and survival outcome was also evaluated in subgroup patients stratified by SUVmax level.

Results

A total of 425 patients treated with either surgery (325) or SBRT (100) were included. Patients receiving SBRT were significantly older, had a higher level of SUVmax and were more likely to have tumor of centrally located. Multivariate analysis showed that SUVmax and tumor size were significant predictors for 3-year OS, LRC, and PFS, while better PFS was also related to peripheral tumor and surgery. The result of PSM analysis also showed that compared to SBRT, surgery could only achieve better PFS. Subgroup analysis indicated that surgery had added advantage of 3-year LRC and PFS for patients in high SUVmax group (SUVmax > 8), but not in low SUVmax group.

Conclusions

The study found a superior PFS after surgery while OS and LRC did not differ between SBRT and surgery. Surgery should be recommended for tumor of high SUVmax.



http://ift.tt/2qXiZ5b

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases

This study investigates the association between immunotherapy and symptomatic radiation necrosis in patients with melanoma, non–small-cell lung cancer, or renal cell carcinoma and newly diagnosed brain metastases treated with stereotactic radiation therapy.

from Cancer via ola Kala on Inoreader http://ift.tt/2qSOFIR
via IFTTT

Neoadjuvant Systemic Therapy for Breast Cancer Searching for More Effectively Curative Therapies

Pathologic complete response (pCR) after neoadjuvant systemic therapy for localized breast cancer is associated with reduced risk of systemic recurrence. Compared with the traditional approach of empirically testing new agents in the adjuvant setting and waiting years for the results to be available, use of pCR as an intermediate pharmacodynamic biomarker offers the potential to accelerate testing of novel treatment approaches, and improve the probability of success in larger, more definitive trials with disease recurrence end points. Other advantages of aiming for higher pCR rates include the potential for less axillary surgery and higher breast conservation rates. The promise of this approach led the US Food and Drug Administration to accept pCR as an end point supporting accelerated regulatory approval of drugs in this setting. Randomized clinical trials have shown that systemic therapy has similar effects whether given before surgery as neoadjuvant therapy or after surgery as adjuvant therapy, providing additional support for this approach. Important caveats include the need for achieving large absolute improvements in pCR rates in order to translate into recurrence-free survival gains, and that full regulatory approval requires confirmation of improved event-free survival in the same trial showing improved pCR, or a separate confirmatory trial. This regulatory pathway has generated much interest in testing drugs in the neoadjuvant setting.

from Cancer via ola Kala on Inoreader http://ift.tt/2msODCD
via IFTTT

Lung Immune Prognostic Index for Advanced Non–Small Cell Lung Cancer

This cohort study investigates whether the pretreatment derived neutrophils/(leukocytes minus neutrophils) ratio and lactate dehydrogenase level are associated with resistance to immunotherapy in patients with advanced non–small cell lung cancer.

from Cancer via ola Kala on Inoreader http://ift.tt/2qXdF1H
via IFTTT

Treating ERBB2/HER-2 –Negative Breast Cancer With Nab-paclitaxel

This randomized clinical trial determines whether nab-paclitaxel improves the outcomes of early and locally advanced ERBB2/HER2-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.

from Cancer via ola Kala on Inoreader http://ift.tt/2D5qgp1
via IFTTT

Association of Oral Microbiome with Risk for Incident Head and Neck Squamous Cell Cancer

This nested case-control study uses 2 large US cohorts to examine the association of the oral microbiome with subsequent risk of head and neck squamous cell cancer.

from Cancer via ola Kala on Inoreader http://ift.tt/2APGAo1
via IFTTT